Development of nitroxide-based theranostic compounds that act both as anti-inflammatory drugs and brain redox imaging probes in MRI.

Theranostic probes provide both therapeutic and diagnostic imaging capabilities in one molecule and show significant promise for use in magnetic resonance imaging (MRI) examinations. The present study describes for the first time the synthesis and utility of nitroxide-based contrast agents exhibiting a nonsteroidal anti-inflammatory drug effect. The target theranostic probes were prepared by connecting the carboxyl group of ibuprofen or ketoprofen to the hydroxyl group of 3-hydroxymethyl-2,2,5,5-tetramethylprrolidine-1-oxyl by a condensation reaction in the presence of dicyclohexylcarbodiimide and 4-dimethylaminopyridine in dichloromethane. MRI of mouse heads after administration of either synthesized theranostic probe indicated that the probes enter the brain by passing through the blood-brain barrier (BBB), resulting in T1 contrast enhancement in mouse brain. This enhancement persisted for the duration of the half-life of about 40 min, which is longer than that obtained by most of pyrrolidine nitroxide molecules. The therapeutic capacities of these theranostic probes were examined using a lipopolysaccharide (LPS)-induced brain inflammation model. The production of nitric oxide, an inflammation marker in septic mouse brain induced by LPS, was remarkably inhibited by the addition of either synthesized probe, indicating that they also act as anti-inflammatory drugs. The present results indicate that nitroxide-based theranostic probes act as both BBB-permeable redox-sensitive contrast agents and as an anti-inflammatory drug in septic mouse brain.